Clinuvel Pharmaceuticals Ltd (CLVLY) SPON ADR EACH REPR 10 NPV

Sell:$7.31Buy:$7.31No change

Prices delayed by at least 15 minutes
Sell:$7.31
Buy:$7.31
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:$7.31
Buy:$7.31
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

Key people

Philippe J. Wolgen
Chief Executive Officer, Managing Director, Executive Director
Peter Vaughan
Chief Financial Officer
Lachlan Hay
Chief Operations Officer
Rose Quadbeck-Diel
Senior Vice President - Regulatory Affairs
Dennis J. Wright
Chief Scientific Officer
Antonella Colucci
Vice President - Commercial Affairs
Malcolm Bull
Head of Australian Operations and Investor Relations
Azza Hamila
Head of Quality Assurance and Drug Safety
Emilie Rodenburger
Director - Global Clinical Affairs
Linda Teng
Director of North American Operations
Jeffrey V. Rosenfeld
Non-Executive Chairman of the Board
Pearl E. Grimes
Non-Executive Director
Matthew Pringle
Non-Executive Director
Guy van Dievoet
Non-Executive Director
Karen A. Agersborg
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Australia
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1887691038
  • Market cap
    $0.00
  • Employees
    16
  • Shares in issue
    50.08m
  • Exchange
    Australian Stock Exchange Ltd
  • Index
    ASX All Ordinaries Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.